Tag: AstraZeneca
Pathos AI bets $125M on ADC its agent platform flagged
Pathos AI is paying $125M upfront for an Alphamab Oncology ADC that its Foundry agent platform flagged, plus a new…
AstraZeneca taps AI to de-risk late-stage trials and speed up filings
AstraZeneca CEO Pascal Soriot said the company is using AI to de-risk late-stage clinical trials and accelerate regulatory submissions.
AI shrinks drug discovery timelines with data-driven biologics design
MIT Technology Review explores how AstraZeneca and others use AI to compress drug discovery and target previously untreatable diseases.